Session

Back to Programme Overview

Renal cell carcinoma treatment: The search for the right strategy

Poster Session 58

  • Location:
    Room 7, Capital suite (level 3)
  • Chairs:
     S. Fernández-Pello Montes, Gijón (ES)
     F. Porpiglia, Turin (IT)
     I. Sinescu, Bucharest (RO)
  • Aims and objectives of this session

    To discuss various aspects which impact the indication for RCC therapy.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
769
Modified 5-item frailty index is associated with increased healthcare resource utilization following elective minimally invasive radical nephrectomy

By: Xia L., Taylor B., Guzzo T.

Institutes: University of Pennsylvania, Perelman School of Medicine, Division of Urology, Dept. of Surgery, Philadelphia, United States of America

770
Is a preoperative low ejection fraction a risk factor for complications and impaired survival in renal cancer patients who undergo surgery? Results from a propensity-score matching with non cardiopathic counterparts

By: Nini A.1, Larcher A.1, Muttin F.1, Zaffuto E.1, Dell’Oglio P.1, Ripa F.1, Carenzi C.1, La Croce G.1, Oppizzi M.2, Fragasso G.2, Montorsi F.1, Capitanio U.1, Bertini R.1

Institutes: 1IRCCS San Raffaele, Dept. of Urology, Division of Oncology/Unit of Urology, URI, Milan, Italy, 2IRCCS San Raffaele, Dept. of Cardiology, Milan, Italy

771
The ability of three comorbity indeces to predict postosperative mortality in renal cell carcinoma patients: The impending need of a new disease-specific index

By: Dell’Oglio P., Larcher A., Muttin F., Fossati N., Nini A., Ripa F., La Croce G., Trevisani F., Carenzi C., Salonia A., Briganti A., Montorsi F., Bertini R., Capitanio U.

Institutes: IRCCS Ospedale San Raffaele, Urological Research Institute, Dept. of Oncology and Urology, Milan, Italy

772
Should partial nephrectomy be considered an imperative indication in stage II chronic kidney disease?

By: Hamilton Z.1, Larcher A.3, Lane B.2, Capitanio U.3, Hassan A-E.1, Berquist S.1, Dufour C.1, Beksac A.T.1, Wan F.1, Proudfoot J.1, Derweesh I.1, Montorsi F.3

Institutes: 1Moores Cancer Center, Dept. of Urology, La Jolla, United States of America, 2Spectrum Health, Dept. of Urology, Grand Rapids, United States of America, 3San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy

773
Tumor size is associated with compensatory hypertrophy in the contralateral kidney before and after radical nephrectomy in patients with renal cell carcinoma

By: Park B.H., Bae S.R., Lee Y.S., Kang S.H., Han C.H.

Institutes: Uijeongbu St. Mary’s Hospital, Dept. of Urology, Uijeongbu-Si, South Korea

774
Clinical application of calculated split renal volume using computed tomography-based renal volumetry after partial nephrectomy: Correlation with 99mTc-DMSA renal scan data

By: Lee C.H., Ku J.Y., Ha H.K.

Institutes: Pusan National University Hospital, Dept. of Urology, Busan, South Korea

775
Functional data as assessed by renal scintigraphy and volumetric assessment on CT-scan prior and after partial nephrectomy. Is there a correlation?

By: Porpiglia F.1, Bertolo R.1, Amparore D.1, Piramide F.1, Checcucci E.1, Angusti T.2, Barrera M.3, Sardo D.3, Veltri A.3, Mele F.1, Fiori C.1

Institutes: 1San Luigi Hospital, Dept. of Urology, Turin, Italy, 2San Luigi Hospital, Dept. of Nuclear Medicine, Turin, Italy, 3San Luigi Hospital, Dept. of Radiology, Turin, Italy

776
Characterisation of solid renal tumours with magnetic resonance elastography (MRE) at 3T: Integrating biomechanical, morphological and functional assessment

By: Prezzi D.1, Neji R.2, Stirling J.1, Jeljeli S.1, Verma H.3, O’Brien T.4, Challacombe B.4, Fernando A.4, Chandra A.6, Sinkus R.5, Goh V.1

Institutes: 1King’s College London, Dept. of Cancer Imaging, London, United Kingdom, 2Siemens Healthineers, Dept. of MR Research Collaborations, Frimley, United Kingdom, 3Guy’s and St Thomas’ NHS Foundation Trust, Dept. of Radiology, London, United Kingdom, 4Guy’s and St Thomas’ NHS Foundation Trust, Dept. of Urology, London, United Kingdom, 5King’s College London, Dept. of Biomedical Engineering, London, United Kingdom, 6Guy’s and St Thomas’ NHS Foundation Trust, Dept. of Pathology, London, United Kingdom

777
Discrimination of malignant and benign kidney tissue with 1064 nm dispersive Raman spectroscopy

By: Haifler M.1, Pence I.2, Ristau B.1, Greenberg R.1, Chen D.1, Smaldone M.1, Kutikov A.1, Viterbo R.1, Uzzo R.1, Zisman A.3, Mahadeven-Jensen A.2, Patil C.4

Institutes: 1Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America, 2Vanderbilt University, Dept. of Biomedical Engineering, Nashville, United States of America, 3Assaf Harofe Medical Center, Dept. of Urology, Be’er Ya’akov, Israel, 4Temple University, Dept. of Biomedical Engineering, Philadelphia, United States of America

778
Topographic distribution of sentinel lymph nodes in patients with renal tumours

By: Kuusk T.1, Grivas N.1, Donswijk M.2, Prevoo W.3, Horenblas S.1, Bex A.1

Institutes: 1Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, 2Netherlands Cancer Institute, Dept. of Nuclear Medicine, Amsterdam, The Netherlands, 3Netherlands Cancer Institute, Dept. of Radiology, Amsterdam, The Netherlands

779
The effect of anatomical location of retroperitoneal lymph node metastases on cancer specific survival in patients with clear cell renal cell carcinoma

By: Nini A.1, Larcher A.1, Terrone C.2, Volpe A.2, Muttin F.1, Ripa F.1, Regis F.2, Lucianò R.3, Briganti A.1, Bertini R.1, Montorsi F.1, Capitanio U.1

Institutes: 1IRCCS San Raffaele, Dept. of Urology, Division of Oncology, Milan, Italy, 2University Hospital Maggiore Della Carità, University of Piemonte Orientale, Dept. of Urology, Novara, Italy, 3IRCCS San Raffaele, Dept. of Pathology, Milan, Italy

780
Lymph node dissection is not associated with increased 30-day complications among patients undergoing radical nephrectomy for renal cell carcinoma: A propensity-score based analysis

By: Gershman B.1, Moreira D.2, Thompson R.H.3, Boorjian S.3, Lohse C.4, Costello B.5, Cheville J.6, Leibovich B.3

Institutes: 1Rhode Island Hospital And The Miriam Hospital, Dept. of Urology, Providence, United States of America, 2University of Illinois, Dept. of Urology, Chicago, United States of America, 3Mayo Clinic, Dept. of Urology, Rochester, United States of America, 4Mayo Clinic, Health Sciences Research, Rochester, United States of America, 5Mayo Clinic, Dept. of Oncology, Rochester, United States of America, 6Mayo Clinic, Dept. of Pathology, Rochester, United States of America

V14
Laparoscopic inter-aorto-caval lymph-node dissection for RCC

By: Bass R., Sidi A., Tsivian A.

Institutes: E. Wolfson M. C., Dept. of Urologic Surgery, Holon, Israel